StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note published on Thursday morning. The firm issued a sell rating on the stock.

CANF has been the subject of a number of other reports. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, December 31st. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Trading Up 1.1 %

Shares of NYSE CANF opened at $1.81 on Thursday. The stock’s 50-day moving average is $1.85 and its 200 day moving average is $2.35. The stock has a market cap of $6.41 million, a price-to-earnings ratio of -1.01 and a beta of 1.32. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC increased its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.